Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer
“We are delighted to have Judith join our leadership at this important juncture for the Company with the recent initiation of the Phase 1/2 Brilliance trial of EDIT-101 (AGN-151587) for the treatment of patients with Leber congenital amaurosis 10 (LCA10),” said
“Editas Medicine is playing a crucial role in the development of a new class of medicines through CRISPR-based genome editing. It is an exciting time to join the team as we are enrolling the first ever clinical trial to investigate an in vivo CRISPR-based experimental medicine,” said
Dr. Abrams has more than 25 years of experience in leadership roles in the biopharmaceutical industry managing portfolios of products across all phases of global clinical development. Dr. Abrams joins
Among her prior roles, Dr. Abrams served as Chief Medical Officer at
Dr. Abrams received her M.D. degree and completed fellowships in Internal Medicine and Rheumatology at the
In connection with Dr. Abrams’ appointment, the Editas Board of Directors approved a stock option grant and a restricted stock unit award to Dr. Abrams. The stock option grant and the restricted stock unit award were granted as inducements material to Dr. Abrams entering into employment with
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the Company’s plans with respect to the Brilliance Phase 1/2 clinical trial for EDIT-101 (AGN-151587). The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
Source: Editas Medicine, Inc.